{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:43:38Z","timestamp":1785242618545,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have increased our ability to treat an ever-expanding number of cancers. We describe a case series of 25 patients who were diagnosed with gastritis following ICI therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This was a retrospective study involving 1712 patients treated for malignancy with immunotherapy at Cleveland Clinic from January 2011 to June 2019 (IRB 18-1225). We searched electronic medical records using ICD-10 codes for gastritis diagnosis confirmed on endoscopy and histology within 3 months of ICI therapy. Patients with upper gastrointestinal tract malignancy or documented Helicobacter pylori-associated gastritis were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-five patients were found to meet the criteria for diagnosis of gastritis. Of these 25 patients, most common malignancies were non\u2013small cell lung cancer (52%) and melanoma (24%). Median number of infusions preceding symptoms was 4 (1-30) and time to symptom onset 2 (0.5-12) weeks after last infusion. Symptoms experienced were nausea (80%), vomiting (52%), abdominal pain (72%), and melena (44%). Common endoscopic findings were erythema (88%), edema (52%), and friability (48%). The most common diagnosis of pathology was chronic active gastritis in 24% of patients. Ninety-six percent received acid suppression treatment and 36% of patients also received steroids with an initial median dose of prednisone 75 (20-80) mg. Within 2 months, 64% had documented complete resolution of symptoms and 52% were able to resume immunotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients presenting with nausea, vomiting, abdominal pain, or melena following immunotherapy should be assessed for gastritis and if other causes are excluded, may require treatment as consideration for complication of immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad031","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T16:38:38Z","timestamp":1678552718000},"page":"706-713","source":"Crossref","is-referenced-by-count":22,"title":["Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center"],"prefix":"10.1093","volume":"28","author":[{"given":"Natalie","family":"Farha","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S","family":"Allende","sequence":"additional","affiliation":[{"name":"Pathology Department, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7390-5949","authenticated-orcid":false,"given":"Joseph","family":"Sleiman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Farha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8626","authenticated-orcid":false,"given":"Pauline","family":"Funchain","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R","family":"Philpott","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"2023080322074524200_CIT0001","first-page":"252","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume-title":"Nat Rev Cancer","author":"Pardoll","year":"2012"},{"key":"2023080322074524200_CIT0002","first-page":"2443","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume-title":"N Engl J Med","author":"Topalian","year":"2012"},{"key":"2023080322074524200_CIT0003","first-page":"vii59","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume-title":"Rheumatology","author":"Weinmann","year":"2019"},{"key":"2023080322074524200_CIT0004","first-page":"711","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume-title":"N Engl J Med","author":"Hodi","year":"2010"},{"key":"2023080322074524200_CIT0005","first-page":"2375","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume-title":"Ann Oncol","author":"Naidoo","year":"2015"},{"key":"2023080322074524200_CIT0006","first-page":"2018","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume-title":"N Engl J Med","author":"Garon","year":"2015"},{"key":"2023080322074524200_CIT0007","first-page":"4712","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume-title":"Proc Natl Acad Sci USA","author":"Hodi","year":"2003"},{"key":"2023080322074524200_CIT0008","first-page":"1199","article-title":"Biomarkers associated with checkpoint inhibitors","volume-title":"Ann Oncol","author":"Manson","year":"2016"},{"key":"2023080322074524200_CIT0009","first-page":"531","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume-title":"Histopathology","author":"Johncilla","year":"2020"},{"key":"2023080322074524200_CIT0010","first-page":"233","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume-title":"Histopathology","author":"Zhang","year":"2020"},{"key":"2023080322074524200_CIT0011","doi-asserted-by":"crossref","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","author":"Tang","year":"2019"},{"key":"2023080322074524200_CIT0012","first-page":"2860","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","author":"Collins","year":"2017"},{"key":"2023080322074524200_CIT0013","first-page":"191","article-title":"Immune checkpoint inhibitor\u2013induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, helicobacter pylori gastritis and celiac disease","volume-title":"Arch Pathol Lab Med","author":"Irshaid","year":"2021"},{"key":"2023080322074524200_CIT0014","first-page":"10013-1","article-title":"Patterns of lymphocytic gastritis may reflect the underlying etiology","volume-title":"Laboratory Investigation","author":"Cui","year":"2016"},{"key":"2023080322074524200_CIT0015","first-page":"210","article-title":"Helicobacter pylori and other gastric microbiota in gastroduodenal pathologies","volume-title":"Dig Dis","author":"Schulz","year":"2016"},{"key":"2023080322074524200_CIT0016","first-page":"e18927","article-title":"Clinical characteristics of cytomegalovirus gastritis: a retrospective study from a tertiary medical center","volume-title":"Medicine","author":"Chen","year":"2020"},{"key":"2023080322074524200_CIT0017","first-page":"S1139","article-title":"The Epstein Barr virus: an unusual source of gastritis: 2342","volume-title":"Am J Gastroenterol","author":"Patel","year":"2016"},{"key":"2023080322074524200_CIT0018","first-page":"743","article-title":"Epstein-Barr virus gastritis","volume-title":"Intern Med","author":"Oki","year":"2017"},{"key":"2023080322074524200_CIT0019","first-page":"533","article-title":"The differential diagnosis of Helicobacter pylori negative gastritis","volume-title":"Virchows Arch","author":"El-Zimaity","year":"2018"},{"key":"2023080322074524200_CIT0020","doi-asserted-by":"crossref","DOI":"10.1053\/j.semdp.2014.02.008","article-title":"Pathology and differential diagnosis of chronic, noninfectious gastritis","volume-title":"Seminars in diagnostic pathology","author":"Polydorides","year":"2014"},{"key":"2023080322074524200_CIT0021","first-page":"419","article-title":"Gastric sarcoidosis and review of the literature","volume-title":"J Natl Med Assoc","author":"Afshar","year":"2010"},{"key":"2023080322074524200_CIT0022","first-page":"836","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume-title":"Clin Gastroenterol Hepatol","author":"Verschuren","year":"2016"},{"key":"2023080322074524200_CIT0023","first-page":"581","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume-title":"Cancer Immunol Immunother.","author":"Bergqvist","year":"2017"},{"key":"2023080322074524200_CIT0024","first-page":"226","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume-title":"J Immunother Cancer","author":"Badran","year":"2019"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/706\/51034809\/oyad031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/706\/51034809\/oyad031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:09:05Z","timestamp":1691100545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/706\/7076255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,11]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad031","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,11]]}}}